Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28040368 | 0.97 | RAPGEF4 (0.30) | RAPGEF4 | |
| SCHEMBL9540860 | 0.80 | ALDH1A1 (0.31) | — | |
| SCHEMBL4753068 | 0.73 | SOS1 (0.31) | — | |
| SCHEMBL3293550 | 0.73 | CA1 (0.58) | — | |
| SCHEMBL5610142 | 0.73 | ALDH1A1 (0.58) | — | |
| SCHEMBL1007834 | 0.73 | CYP3A4 (0.52) | RAPGEF4 | |
| SCHEMBL395085 | 0.71 | CYP3A4 (0.33) | — | |
| SCHEMBL28891533 | 0.71 | MEN1 (0.35) | — | |
| SCHEMBL1551822 | 0.69 | RAPGEF4 (0.59) | RAPGEF4 | |
| SCHEMBL28951 | 0.69 | RAPGEF4 (0.59) | RAPGEF4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1187 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106103463-B | Bridging type nucleosides and nucleotide | 国立大学法人大阪大学 | 2018-11-30 | — | — | CN | claimed |
| EP-3109254-B1 | CROSSLINKED NUCLEOSIDE AND NUCLEOTIDE | UNIV OSAKA (JP) | 2018-04-11 | — | — | EP | claimed |
| EP-1152009-B2 | NOVEL NUCLEOSIDES AND OLIGONUCLEOTIDE ANALOGUES | DAIICHI SANKYO CO LTD (JP) | 2017-09-06 | — | — | EP | claimed |
| US-7335765-B2 | Nucleoside and oligonucleotide analogues | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2008-02-26 | — | — | US | claimed |
| EP-3904360-B1 | NOVEL TETRAARYLBORATE COMPOUND, CATALYST COMPOSITION COMPRISING SAME, AND METHOD FOR PREPARING ETHYLENE HOMOPOLYMERS OR COPOLYMERS OF ETHYLENE AND ALPHA-OLEFIN BY USING SAME | SABIC SK NEXLENE COMPANY PTE LTD (SG) | 2024-07-03 | — | — | EP | disclosed |
| US-20240208999-A1 | HETEROCYCLIC COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-06-27 | — | — | US | disclosed |
| CN-113677686-B | Novel tetraarylborate compounds, catalyst compositions comprising the same, and process for preparing ethylene homopolymers or copolymers of ethylene and alpha-olefins by using the same | 沙特基础工业爱思开NEXLENE私人有限公司 | 2024-06-11 | — | — | CN | disclosed |
| CN-113387055-B | Film, method for producing film, and bag | 住友化学株式会社 | 2024-06-07 | — | — | CN | disclosed |
| EP-4370507-A1 | HYDROGENATED QUINOXALINES | Otsuka Pharmaceutical Co., Ltd. (JP) | 2024-05-22 | — | — | EP | disclosed |
| WO-2024101446-A1 | MODIFIED NUCLEOSIDE HAVING GUANIDINO STRUCTURE IN BRIDGED PART AND METHOD FOR PRODUCING OLIGONUCLEOTIDE USING SAME | ルクサナバイオテク株式会社 | 2024-05-16 | — | — | WO | disclosed |
| WO-2024101258-A1 | COMPOUND, POLYMERIZABLE COMPOSITION, ADHESIVE, RESIN CURED PRODUCT, MOLDED ARTICLE, FILM, PRESSURE-SENSITIVE ADHESIVE, AND METHOD FOR PRODUCING COMPOUND | 三井化学株式会社 | 2024-05-16 | — | — | WO | disclosed |
| CN-112513062-B | Oligonucleotide-containing small cell lung cancer therapeutic agent | 国立大学法人大阪大学 | 2024-05-10 | — | — | CN | disclosed |
| US-4487772-A | CARDIOTONIC AGENTS | OTSUKA PHARMACEUTICAL CO. LTD. (JP) | 1984-12-11 | — | — | US | disclosed |
| US-4468402-A | Carbostyril derivatives, process for producing the same and cardiotonic compositions containing the same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1984-08-28 | — | — | US | disclosed |
| US-4455430-A | ANTITUMOR AGENTS, MICROCIDES | THE UPJOHN COMPANY (US) | 1984-06-19 | — | — | US | disclosed |
| US-4454130-A | CARDIOTONIC, HYPOTENSIVE AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1984-06-12 | — | — | US | disclosed |
| US-RE31578-E | ANTITUMOR AGENTS, BACTERICIDES | THE UPJOHN COMPANY (US) | 1984-05-01 | — | — | US | disclosed |
| US-4298744-A | CHLORINATION OF ISOMERIC ANALOG | THE UPJOHN COMPANY (US) | 1981-11-03 | — | — | US | disclosed |
| US-4275214-A | ANALOGS OF TRICHOLOMIC ACID USEFUL AS INTERMEDIATES IN THE PREPARATION OF AT-125 | THE UPJOHN COMPANY (US) | 1981-06-23 | — | — | US | disclosed |
| US-4256898-A | INTERMEDIATES FOR MAKING (ALPHAS, 5S)-ALPHA-AMINO-3-CHLORO-2-ISOXAZOLINE-5-ACETIC ACID (AT-125) | THE UPJOHN COMPANY (US) | 1981-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240208999-A1 | HETEROCYCLIC COMPOUND | AHR, PDGFRA, PDGFRB | RAPGEF4 1430/4885TUBB1 4378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.